LobbyingF Hoffmann-La Roche LTD and Its Affiliates lobbying by quarter
F Hoffmann-La Roche LTD and Its Affiliates's latest lobbying report covers Q2 2026, at $90K. The four quarters Q3 2025–Q2 2026 total $430K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
F Hoffmann-La Roche LTD and Its Affiliates
- Latest quarter
- $90K
- Q2 2026 · 1 reports
- Last 12 months
- $430K
- Last 4 quarters
- vs last quarter
- −43.8%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $120K | 1 |
| Q1 2023 | $150K | 1 |
| Q2 2023 | $140K | 1 |
| Q3 2023 | $120K | 1 |
| Q4 2023 | $150K | 1 |
| Q1 2024 | $180K | 1 |
| Q2 2024 | $80K | 1 |
| Q3 2024 | $90K | 1 |
| Q4 2024 | $110K | 1 |
| Q1 2025 | $130K | 1 |
| Q2 2025 | $100K | 1 |
| Q3 2025 | $90K | 1 |
| Q4 2025 | $90K | 1 |
| Q1 2026 | $160K | 1 |
| Q2 2026 | $90K | 1 |
Policy issues the reports name
- Health issues15 reports
- Medical research and clinical labs15 reports
- Medicare and Medicaid15 reports
- Foreign relations13 reports
- Defense2 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES15 reports
- SENATE15 reports
- Health & Human Services, Dept of (HHS)8 reports
- State, Dept of (DOS)7 reports
- U.S. Agency for International Development (USAID)7 reports
- Natl Institutes of Health (NIH)5 reports
- White House Office5 reports
- Food & Drug Administration (FDA)4 reports
- Centers For Medicare and Medicaid Services (CMS)2 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseF. Hoffmann-La Roche LTD, and Its Affiliates | $1.8M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/15for Q2 | In-house | $90K |
| 04/15for Q1 | In-house | $160K |
| 01/14for Q4 2025 | In-house | $90K |
| 25/10/19for Q3 2025 | In-house | $90K |
| 25/07/14for Q2 2025 | In-house | $100K |
| 25/04/16for Q1 2025 | In-house | $130K |
| 25/01/16for Q4 2024 | In-house | $110K |
| 24/10/15for Q3 2024 | In-house | $90K |
| 24/07/17for Q2 2024 | In-house | $80K |
| 24/04/17for Q1 2024 | In-house | $180K |
| 24/01/18for Q4 2023 | In-house | $150K |
| 23/10/09for Q3 2023 | In-house | $120K |
| 23/07/14for Q2 2023 | In-house | $140K |
| 23/04/17for Q1 2023 | In-house | $150K |
| 23/01/18for Q4 2022 | In-house | $120K |